Table 1.
P2022 (7) | S2022 (24) | K2016 (3) | H2017 (19) | G2018 (23) | M2018 (18) | G1993 (11) | S1997 (13) | S2011 (20) | A2023 (15) | M2000 (10) | D2011 (1) | J2012 (21) | N2002 (16) | Y2010 (17) | T2006 (22) | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Define the source of information (survey, record review) | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
List inclusion and exclusion criteria for exposed and unexposed subjects (cases and controls) or refer to previous publications | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
Indicate time period used for identifying patients | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 0 |
Indicate whether or not subjects were consecutive if not population-based | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 1 |
Indicate if evaluators of subjective components of study were masked to other aspects of the status of the participants | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Describe any assessments undertaken for quality assurance purposes (e.g., test/retest of primary outcome measurements) | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 1 |
Explain any patient exclusions from analysis | 0 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 1 |
Describe how confounding was assessed and/or controlled. | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
If applicable, explain how missing data were handled in the analysis | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
Summarize patient response rates and completeness of data collection | 0 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 |
Clarify what follow-up, if any, was expected and the percentage of patients for which incomplete data or follow-up was obtained | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Count | 6 | 6 | 5 | 7 | 4 | 3 | 5 | 3 | 4 | 4 | 5 | 4 | 3 | 8 | 5 | 5 |